INTERVIEW: Tapping China Expertise, Market Core To Celsion’s ThermoDox Plans
This article was originally published in PharmAsia News
Celsion, a US company specialized in oncology, is advancing its new China OPTIMA study with ThermoDox, a doxorubicin preparation for primary liver cancer. CEO Michael Tardugno sat down with PharmAsia News to talk about the ongoing clinical process and the Nasdaq-listed firm’s broader development and commercial plans, in which China plays a key role.
Register for our free email digests: